Resistance of Muscle to Tumor Metastases: A Role for A3 Adenosine Receptor Agonists

Tumor metastases are extremely rare in striated muscles. Lately, we have found that muscle cell conditioned medium (MCM) inhibits the proliferation of various tumor cells while maintaining the growth of normal murine bone marrow cells. This dual activity was confirmed in vivo when the MCM was admini...

Full description

Bibliographic Details
Main Authors: Sara Bar-Yehuda, Faina Barer, Lea Volisson, Pnina Fishman
Format: Article
Language:English
Published: Elsevier 2001-01-01
Series:Neoplasia: An International Journal for Oncology Research
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558601800245
_version_ 1818236306043437056
author Sara Bar-Yehuda
Faina Barer
Lea Volisson
Pnina Fishman
author_facet Sara Bar-Yehuda
Faina Barer
Lea Volisson
Pnina Fishman
author_sort Sara Bar-Yehuda
collection DOAJ
description Tumor metastases are extremely rare in striated muscles. Lately, we have found that muscle cell conditioned medium (MCM) inhibits the proliferation of various tumor cells while maintaining the growth of normal murine bone marrow cells. This dual activity was confirmed in vivo when the MCM was administered orally, i.e., it inhibited the development of tumor growth in mice and prevented the myelotoxic effects of chemotherapy. Adenosine was found to be one of the active components of MCM, inhibiting tumor cell growth while maintaining bone marrow cell proliferation in vitro. Adenosine is known to act as an important regulatory molecule through its binding to specific Gprotein-associated A1, A2a, A2b, and A3 cell surface receptors. In distinction from MCM, adenosine did not suppress tumor development in mice and was not active as a chemoprotective agent when administered orally or intravenously. Thus, the in vivo activity of MCM could not be attributed to adenosine. In this study, MCM from which adenosine was enzymatically removed still retained its dual activity that was also found to be mediated through the A3 adenosine receptor (A3AR). This result led to the conclusion that natural agonists to A3AR were responsible for the activity of MCM. We further tested synthetic agonist to the A3AR and demonstrated that it possessed the same in vitro and in vivo activity profile as MCM. Taken together, muscle cells, in addition to adenosine, secrete natural agonists to A3AR. These agonists are stable nondegradable molecules and may contribute to the systemic anticancer and chemoprotective activity exerted by MCM. This group of molecules may account for the rarity of tumor metastases in muscle.
first_indexed 2024-12-12T12:07:46Z
format Article
id doaj.art-e97b266c893a4586bb23bd9cb7743189
institution Directory Open Access Journal
issn 1476-5586
1522-8002
language English
last_indexed 2024-12-12T12:07:46Z
publishDate 2001-01-01
publisher Elsevier
record_format Article
series Neoplasia: An International Journal for Oncology Research
spelling doaj.art-e97b266c893a4586bb23bd9cb77431892022-12-22T00:24:58ZengElsevierNeoplasia: An International Journal for Oncology Research1476-55861522-80022001-01-013212513110.1038/sj.neo.7900138Resistance of Muscle to Tumor Metastases: A Role for A3 Adenosine Receptor AgonistsSara Bar-YehudaFaina BarerLea VolissonPnina FishmanTumor metastases are extremely rare in striated muscles. Lately, we have found that muscle cell conditioned medium (MCM) inhibits the proliferation of various tumor cells while maintaining the growth of normal murine bone marrow cells. This dual activity was confirmed in vivo when the MCM was administered orally, i.e., it inhibited the development of tumor growth in mice and prevented the myelotoxic effects of chemotherapy. Adenosine was found to be one of the active components of MCM, inhibiting tumor cell growth while maintaining bone marrow cell proliferation in vitro. Adenosine is known to act as an important regulatory molecule through its binding to specific Gprotein-associated A1, A2a, A2b, and A3 cell surface receptors. In distinction from MCM, adenosine did not suppress tumor development in mice and was not active as a chemoprotective agent when administered orally or intravenously. Thus, the in vivo activity of MCM could not be attributed to adenosine. In this study, MCM from which adenosine was enzymatically removed still retained its dual activity that was also found to be mediated through the A3 adenosine receptor (A3AR). This result led to the conclusion that natural agonists to A3AR were responsible for the activity of MCM. We further tested synthetic agonist to the A3AR and demonstrated that it possessed the same in vitro and in vivo activity profile as MCM. Taken together, muscle cells, in addition to adenosine, secrete natural agonists to A3AR. These agonists are stable nondegradable molecules and may contribute to the systemic anticancer and chemoprotective activity exerted by MCM. This group of molecules may account for the rarity of tumor metastases in muscle.http://www.sciencedirect.com/science/article/pii/S1476558601800245muscletumorA3 adenosine receptoragonists
spellingShingle Sara Bar-Yehuda
Faina Barer
Lea Volisson
Pnina Fishman
Resistance of Muscle to Tumor Metastases: A Role for A3 Adenosine Receptor Agonists
Neoplasia: An International Journal for Oncology Research
muscle
tumor
A3 adenosine receptor
agonists
title Resistance of Muscle to Tumor Metastases: A Role for A3 Adenosine Receptor Agonists
title_full Resistance of Muscle to Tumor Metastases: A Role for A3 Adenosine Receptor Agonists
title_fullStr Resistance of Muscle to Tumor Metastases: A Role for A3 Adenosine Receptor Agonists
title_full_unstemmed Resistance of Muscle to Tumor Metastases: A Role for A3 Adenosine Receptor Agonists
title_short Resistance of Muscle to Tumor Metastases: A Role for A3 Adenosine Receptor Agonists
title_sort resistance of muscle to tumor metastases a role for a3 adenosine receptor agonists
topic muscle
tumor
A3 adenosine receptor
agonists
url http://www.sciencedirect.com/science/article/pii/S1476558601800245
work_keys_str_mv AT sarabaryehuda resistanceofmuscletotumormetastasesarolefora3adenosinereceptoragonists
AT fainabarer resistanceofmuscletotumormetastasesarolefora3adenosinereceptoragonists
AT leavolisson resistanceofmuscletotumormetastasesarolefora3adenosinereceptoragonists
AT pninafishman resistanceofmuscletotumormetastasesarolefora3adenosinereceptoragonists